Prescription Drug and Over-the-Counter Medication Eligibility

Whether a drug counts as an eligible medical expense under a Canadian Health Spending Account comes down to one question: can the drug only be lawfully obtained with a prescription? That single test, drawn from Income Tax Act section 118.2(2)(n), decides nearly every claim dispute before it starts. The statute says a drug is an eligible medical expense only if it "can lawfully be acquired for use by the patient only if prescribed by a medical practitioner or dentist." HSA eligibility tracks the Medical Expense Tax Credit list almost exactly, so this one line of tax law shapes what an HSA can and cannot reimburse. Two conditions have to be true at the same time: the drug must be legally restricted to prescription-only sale, and a registered pharmacist has to be the one dispensing it. A doctor's enthusiasm for a product doesn't enter into it. The test asks whether the law locks the drug behind a prescription pad, not whether a clinician thinks the patient needs it.

The 2008 statutory change

The rule used to be looser. Before 2008, a physician's prescription recorded by a pharmacist could be enough to qualify an over-the-counter product for the tax credit, even if that same product sat on an open shelf for anyone to buy. The Federal 2008 Budget rewrote the Income Tax Act and closed that door: the drug itself now has to be legally unavailable without a prescription. A prescription written for a product that anyone can buy off the shelf no longer changes anything.

That shift still catches people today. Employees and small business owners routinely assume that if their doctor writes something down, an HSA will reimburse it. It won't, unless the product is legally restricted to prescription-only sale. The financial consequence is straightforward: someone pays out of pocket for a product they believed was covered, only to find out the claim gets rejected because the test is about legal status, not medical judgment.

Common medications: what's in and what's out

Applying that single test to everyday medications produces a clean, if sometimes surprising, line. Prescription drugs dispensed by a registered pharmacist clear the bar without complication: maintenance medications like blood pressure drugs, antidepressants, and cholesterol medications all qualify, as do specialty and biologic drugs, eligible medical cannabis with the required documentation, and vaccines dispensed by a pharmacist under prescription. Insulin sits in its own category. It's covered as a standalone CRA-eligible expense without needing a prescription at all, making it the clearest statutory carve-out from the general OTC exclusion.

On the other side of the line, over-the-counter products stay ineligible no matter how real the medical need behind them is. Pain relievers such as Tylenol or Advil don't qualify, nor does cough and cold medicine, multivitamins, general wellness supplements, or protein powders. Non-prescription CBD products fall into the same category. None of these products require a prescription by law, so no amount of medical justification moves them across the line. The rule doesn't ask whether a person needs the product. It asks whether the law lets anyone else buy it too.

The narrow exceptions where OTC products can become eligible, and the limits of those exceptions

A small number of OTC-type products do cross into eligibility, but the path is narrow and the underlying legal test never actually bends. Vitamin B12 is the clearest example: the CRA specifically recognizes B12 therapy for pernicious anaemia as an eligible medical expense, even though B12 itself is an over-the-counter product in other contexts. That carve-out amounts to Parliament's own acknowledgment that the prescription-versus-OTC line doesn't always match clinical reality, at least in this one documented case.

The exception doesn't generalize, though, and this is where a lot of confusion sets in. Many people assume that any vitamin, supplement, or OTC medication becomes eligible the moment a physician prescribes it. That's the "prescribed OTC" misconception, and it costs people money at claim time. A prescription from a doctor doesn't change the legal-availability status of a product that anyone can still buy off the shelf without one. Most vitamins and supplements fail the eligibility test for exactly this reason, prescribed or not. There is a place where a prescription genuinely helps: certain orthotics and some medical devices can become eligible when prescribed for a specific condition. That pathway runs through separate CRA provisions entirely, not through the drug eligibility rule in section 118.2(2)(n), so it doesn't open any new door for OTC medications themselves.

Private group plan requirements on top of the CRA rule

Passing the CRA test is the floor, not the ceiling. Private group plans apply their own exclusion criteria independently of the METC and HSA framework, and those criteria almost always come down harder on OTC products than the tax rule does. Over-the-counter medications are excluded by nearly every private plan, even with a physician's recommendation attached, because they aren't dispensed on prescription. Products without a Drug Identification Number, the eight-digit code Health Canada assigns that shows up on the product label and the pharmacy receipt, get excluded too. Drugs administered in hospital generally fall to provincial health plans instead, and compounded preparations often get excluded outright or only qualify when every individual ingredient is separately an eligible benefit.

This is why a prescription from a doctor can clear the CRA test and still get a claim denied at the group plan level. Meeting the CRA prescription test is necessary, but it isn't sufficient on its own. Each plan adds its own deductibles, coinsurance percentages, dispensing-fee limits, annual maximums, and drug-specific conditions on top of the statutory baseline. For anyone using an HSA to cover what a group plan won't, both layers matter at once: the HSA only reimburses what clears the CRA test, and the group plan's own exclusions determine what gets left over for the HSA to pick up.

GLP-1 drugs as a live test of where the prescription rule meets indication-based coverage limits

GLP-1 receptor agonists like Ozempic and Wegovy, along with dual GIP/GLP-1 receptor agonists like Mounjaro and Zepbound, are prescription drugs and clear the basic CRA eligibility test without issue. Whether a specific patient's use gets covered is a separate question entirely, one that turns on the indication rather than the prescription itself. Provincial public plans cover GLP-1s almost exclusively for type 2 diabetes, and not for weight loss.

Private group plans are moving, though unevenly. The International Foundation of Employee Benefit Plans' 2026 pulse survey found a growing share of Canadian employers now covering GLP-1s for both diabetes and weight management, up from a smaller share in prior years, while a majority of employers still restrict coverage to diabetes only. Among employers that don't currently cover GLP-1s for weight loss, a notable share actively encourage employees to pay for the medications through an HSA instead. That workaround functions because the CRA test doesn't care about indication. An HSA reimbursement for a prescription drug is eligible under CRA rules regardless of why it was prescribed, even in cases where the group plan has excluded that specific use.

How public programs handle OTC drugs differently

Several Canadian public programs cover OTC products for the populations they serve, and that fact matters because it shows the OTC exclusion in the METC and HSA framework is a policy choice, not a rule that has to work this way everywhere. The Ontario Drug Benefit covers some OTC drugs, but only when a physician, nurse practitioner, or other prescriber writes a prescription for the product and the drug either appears on the ODB formulary or qualifies through the Exceptional Access Program. A prescription is necessary there too, but it isn't sufficient on its own, the same two-part structure found in the CRA rule. The Exceptional Access Program route requires meeting clinical criteria and getting approval before the purchase happens, and ODB explicitly advises checking with a healthcare provider before buying an OTC drug, to avoid paying out of pocket for something that won't be reimbursed.

A federal drug benefit program for a specific population covers prescription drugs and a select list of OTC products on its Drug Benefit List, and accepts client-specific written recommendations for those listed OTC products from licensed health professionals acting within their scope of practice. In July 2026, the program added topical aluminum chloride products for the treatment of uncontrollable sweating to its new pharmacy benefit listings, an OTC-category product now accessible as a benefit under that program.

None of this reaches employees and small business owners relying on a private plan or an HSA. These public-plan exceptions exist for the specific populations those programs serve. The private-plan and HSA world still runs on the stricter METC legal test described earlier, with no equivalent exceptional-access pathway built in.

Clinical reality versus the legal rule

The prescription-versus-OTC line tracks historical regulatory status, not therapeutic value. A drug's eligibility depends on how Health Canada happened to classify it, not on how much a given patient actually needs it, so two clinically similar treatments can land on opposite sides of the line for reasons that have nothing to do with medicine. The vitamin B12 exception exists because Parliament itself recognized this incoherence in at least one documented case. That carve-out is a quiet admission that the people who drew the boundary didn't treat it as medically principled even when they drew it.

The GLP-1 weight-management situation stretches that same tension across a much larger population. Covering a molecule for diabetes while refusing to cover the identical molecule for obesity gets harder to justify clinically as cardiovascular evidence reframes GLP-1s as a potentially long-term therapy rather than a short course for shedding weight. There's a structural pressure building on top of this too: telehealth and direct-to-consumer prescribing platforms make it easier for patients to get prescriptions for conditions they used to manage with OTC products on their own. In theory that opens up HSA eligibility for products that were previously out of reach. In practice, this is exactly the kind of grey zone where CRA audit guidance may eventually need to respond.

Navigating the line between covered and not covered

Knowing the prescription-only rule before making a purchase is what keeps spending from turning into a rejected claim after the fact. The first and most useful habit is checking whether a drug legally requires a prescription, not just whether a doctor happened to mention it, and a pharmacist is the clearest source for that answer. Checking that a product has a Drug Identification Number matters too, since that eight-digit code appears on both the product label and the pharmacy receipt, and private plans routinely exclude anything that lacks one. For anything sitting in a grey area, a supplement or an OTC product a doctor has recommended, the right move is asking a pharmacist or benefits administrator before buying it, not after the receipt is already in hand. Holding onto the pharmacy receipt matters as well, since eligible drug claims need documentation showing the prescription was actually dispensed by a registered pharmacist. For prescription drugs a group plan excludes based on indication, GLP-1s prescribed for weight management being the clearest current example, an HSA reimburses the cost without any restriction tied to indication, because the CRA test is satisfied by the prescription itself, independent of what the group plan decided to exclude.